BEAM logo

Beam Therapeutics Inc.

BEAM
Healthcare|Biotechnology|US
$26.41
+0.54 (+2.09%)
Tangible Book / Share
$9.10
Cash / Share
$9.97

Analyst Consensus

Buy28 analysts
Strong Buy
0
Buy
19
Hold
8
Sell
1
Strong Sell
0
Consensus Target
$66.00
Implied Upside
+149.9%
Low Target
$39.00
High Target
$80.00

Price Target Trend

Last Month
$79.00
1 target · +199% vs price
Last Quarter
$79.00
1 target · +199% vs price
Last Year
$49.22
9 targets · +86% vs price
All Time
$50.90
20 targets · +93% vs price

Rating Trend

Dec 25
14 buy · 2 hold · 0 sell
Jan 26
14 buy · 3 hold · 0 sell
Feb 26
15 buy · 2 hold · 0 sell
Mar 26
15 buy · 2 hold · 0 sell
Apr 26
15 buy · 2 hold · 0 sell
May 26
15 buy · 2 hold · 0 sell
Jun 26
15 buy · 2 hold · 0 sell
Jul 26
15 buy · 2 hold · 0 sell
Aug 26
13 buy · 2 hold · 0 sell
Sep 26
13 buy · 2 hold · 0 sell
Oct 26
13 buy · 2 hold · 0 sell
Nov 26
13 buy · 2 hold · 0 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Oct 29, 2026Canaccord Genuity$79.00(+174%)$28.78TheFly
May 21, 2026H.C. WainwrightPatrick Trucchio$80.00(+195%)$27.11StreetInsider
May 13, 2026Tudor PickeringWilliam Pickering$39.00(+23%)$31.58TheFly
Feb 25, 2026RBC Capital$26.00(-16%)$30.83TheFly
Feb 20, 2026Canaccord Genuity$74.00(+165%)$27.88TheFly
Jan 21, 2026Tudor PickeringWilliam Pickering$41.00(+32%)$31.00StreetInsider
Jan 20, 2026Bernstein$41.00(+32%)$30.96TheFly
Jan 7, 2026UBSMichael Yee$28.00(-1%)$28.34StreetInsider
Nov 24, 2025Evercore ISI$35.00(+50%)$23.32TheFly
Oct 9, 2025Jefferies$41.00(+47%)$27.86TheFly
May 7, 2025GuggenheimDebjit Chattopadhyay$55.00(+244%)$15.99TheFly
Mar 3, 2025Scotiabank$25.00(-0%)$25.10TheFly
Jan 7, 2025Tudor PickeringWilliam Pickering$37.00(+37%)$27.08StreetInsider
Nov 6, 2024Leerink PartnersRick Bienkowski$39.00(+60%)$24.34StreetInsider
Nov 5, 2024BMO CapitalKostas Biliouris$57.00(+134%)$24.34StreetInsider
Sep 11, 2024Stifel NicolausBenjamin Burnett$69.00(+196%)$23.34StreetInsider
Feb 1, 2023Cantor Fitzgerald$62.00(+43%)$43.45Benzinga
Dec 20, 2022BMO CapitalKostas Biliouris$66.00(+59%)$41.59StreetInsider
Dec 13, 2022Citigroup$62.00(+29%)$48.19Benzinga
Apr 28, 2022Credit Suisse$62.00(+56%)$39.83Benzinga

Recent Rating Actions

FirmActionRatingDate
GuggenheimmaintainBuyNov 5, 2026
Canaccord GenuitymaintainBuyNov 4, 2026
WedbushmaintainOutperformNov 4, 2026
Canaccord GenuitymaintainBuyOct 29, 2026
WedbushmaintainOutperformOct 28, 2026
HC Wainwright & Co.maintainBuyOct 15, 2026
WedbushmaintainOutperformOct 14, 2026
WedbushmaintainOutperformSep 9, 2026
HC Wainwright & Co.maintainBuyAug 25, 2026
B of A SecuritiesmaintainBuyJul 8, 2026
HC Wainwright & Co.maintainBuyJul 7, 2026
BernsteinmaintainOutperformMay 13, 2026
CitigroupmaintainBuyMar 26, 2026
WedbushmaintainOutperformFeb 25, 2026
RBC CapitalmaintainSector PerformFeb 25, 2026
BernsteinmaintainOutperformJan 21, 2026
HC Wainwright & Co.maintainBuyOct 10, 2025
JP MorganmaintainOverweightOct 9, 2025
HC Wainwright & Co.maintainBuySep 15, 2025
BarclaysmaintainEqual WeightAug 6, 2025
GuggenheimmaintainBuyMay 7, 2025
Wells FargomaintainOverweightMay 7, 2025
BarclaysmaintainEqual WeightMay 7, 2025
HC Wainwright & Co.maintainBuyApr 7, 2025
B of A SecuritiesupgradeNeutral →BuyMar 28, 2025

Earnings History

Next report: Feb 23, 2027 · EPS est. $-1.29
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 3, 2026$-1.28$-1.15$307.0K$8.8M
Aug 4, 2026$-1.18$-1.11$490.0K$16.4M
May 7, 2026$-0.91$-0.87$31.7M$11.0M
Feb 24, 2026$-0.10$-1.13$114.1M$11.7M
Nov 4, 2025$-1.10$-0.98$9.7M$13.2M
Aug 5, 2025$-1.00$-1.04$8.5M$11.5M
May 6, 2025$-1.24$-1.11$7.5M$15.5M
Feb 25, 2025$-1.09$-1.25$30.1M$16.5M

News

Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting

BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base ed…

Nov 4, 2026globenewswire.com
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.

Nov 3, 2026zacks.com
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027

Nov 3, 2026globenewswire.com
3 Promising Genomics Stocks to Add to Your Portfolio Now

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.

Oct 30, 2026zacks.com
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Oct 29, 2026zacks.com
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript

Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript

Oct 27, 2026seekingalpha.com
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance

Beam Therapeutics NASDAQ: BEAM reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvements in fasting tolerance and reductions in cornstarch supplementation among the first six treated patients.

Oct 27, 2026marketbeat.com
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress

In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment  Safety Profile of BEAM-301 Consistent with LNP-Based Therapies Beam Plans to Engage FDA on Potential Path to Approval; Enrollment in 60 mg Dose Cohort Underway Company to Host Investor Webcast Today, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.

Oct 27, 2026globenewswire.com
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) CEO John Evans sold 25,000 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the sale, the chief executive officer owned 1,047,205 shares in the company, valued

Oct 19, 2026defenseworld.net
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

Cathie Wood owns Beam shares worth roughly $220 million, at the stock's current price. All of the company's revenue is collaboration revenue.

Oct 17, 2026fool.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Oct 15, 2026prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Oct 13, 2026globenewswire.com
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse

Short sellers are betting heavily against 10 stocks, and the fuse is getting shorter. Each one has more than 38% of its float sold short, with market caps above $2 billion and average daily volume above 1 million shares, according to Benzinga Pro screener data as of Oct. 12.

Oct 13, 2026benzinga.com
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints Safety Profile of BEAM-301 Consistent with LNP-based Therapies Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.

Oct 13, 2026globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Oct 8, 2026prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Oct 6, 2026globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Oct 1, 2026prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Sep 29, 2026globenewswire.com
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while Risto-cel's blockbuster potential is now downgraded. AI-driven competition, such as Anthropic, is unlikely to disrupt BEAM in the near term; partnerships with AI firms could become a future catalyst.

Sep 29, 2026seekingalpha.com
Squeeze Watch: 10 Stocks With Over 33% Short Interest

Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.

Sep 25, 2026benzinga.com